# PT-141 Dosage Research and Half-Life | Melanocortin Peptide > PT-141 dosage research in plain English: the approved 1.75 mg label dose, the routes studied, and how long PT-141 lasts — study-attributed, no personal dosing advice. What the studies and the approved label document about dose, delivery, and how long it lasts — reported as research, not as instructions. ## The short version This page summarizes **PT-141 dosage** as documented in the studies and the approved drug label — it does not tell anyone what to take. The one approved dose is for women: 1.75 mg injected under the skin, used as needed, at least 45 minutes before sex, with no more than one dose in 24 hours and no more than eight doses a month [7]. How long does it last in the body? After the injection, PT-141 has a half-life (the time for half of it to clear) of about 2.7 hours, ranging roughly 1.9 to 4.0 hours [7]. It is delivered as a subcutaneous injection in the approved form; earlier research also tried a nasal spray and an intravenous route [7][8]. There is no approved male dose, because PT-141 is not approved for men [7]. Everything below is study-attributed. ## PT-141 dosage in the research The doses that appear in the literature are research and label doses, not recommendations. The **approved label dose** is 1.75 mg subcutaneously, as needed, capped at one dose per 24 hours and eight per month [7]. Phase 2 dose-finding in women tested 0.75, 1.25, and 1.75 mg before the 1.75 mg dose was chosen [7]. In the early **male** research, a nasal spray was escalated to roughly 7 to 20 mg, with a statistically significant erectile response appearing above 7 mg [8]. Separate Phase 1 metabolic research in women used subcutaneous doses up to 2.5 mg, several times daily for 15 days, strictly as a research protocol [7]. These figures describe what was given to whom in studies — they are not a guide for any individual, and this site recommends no dose. ## How long does PT-141 last **How long does PT-141 last** has two answers: how long it stays in the body, and how long an effect was observed. In the body, the approved subcutaneous form has a terminal half-life of about 2.7 hours (range 1.9 to 4.0 hours) [7]; early nasal studies reported a slightly shorter 1.85 to 2.09 hours [8]. Peak blood levels arrive quickly — a median of about 0.5 to 1.0 hours after a subcutaneous injection [7]. The observed effect can outlast the drug in the blood. In the 2022 brain-imaging study, a single dose increased desire for **up to 24 hours** — longer than the molecule itself lingers — because the effect is a downstream brain change, not just the presence of the drug [5]. In the early male nasal studies, first erections appeared at about 30 minutes [8]. Other label pharmacokinetics: a volume of distribution near 25 L, clearance about 6.5 L/hr, and excretion mostly via the kidneys (about 65%) and feces (about 23%) [7]. ## PT-141 dosage for women The **PT-141 dosage for women** is the only one with regulatory backing, and it is the approved label dose: 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated sexual activity, with the same caps of one dose per 24 hours and eight per month [7]. That dose was selected from the Phase 2 range (0.75 to 1.75 mg) and carried into the two Phase 3 trials [3][7]. It is approved specifically for premenopausal women with acquired, generalized HSDD, and not for postmenopausal women [7]. The label also carries the blood-pressure caution: people with uncontrolled high blood pressure or known cardiovascular disease should not use it because of a transient post-dose blood-pressure rise [7]. As everywhere on this site, this describes the label — it is not personal medical advice, and no dose is recommended to any reader. --- A wine-dark reading archive of the bremelanotide literature — entries ruled and cited, nothing on these shelves for sale.